Oncotelic extends note maturity to March 2022, issues 22M warrants, CTO Park resigns

Oncotelic Therapeutics, Inc.

Issued $103,750 convertible promissory note to Geneva Roth Remark Holdings on June 28, 2021.
Extended maturity of JH Darbie financing notes from June 30, 2021 to March 31, 2022.
Issued 20M additional Oncotelic warrants to investors and 2M warrants to placement agent J.H. Darbie & Co.
CTO Chulho Park resigned effective July 1, 2021 due to personal health; will continue as part-time consultant.

item 1.01 item 3.02 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chulho Park

Chief Technology Officer

OTLC · Oncotelic Therapeutics, Inc.

Effective: 2021-07-01
Filed: July 2, 2021, 7:59 PM ET

On July 1, 2021, Chulho Park, Ph. D., provided notice to the Company of his intention to resign as the Chief Technology Officer of the Company, to be effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chulho Park resigned as Chief Technology Officer at Oncotelic Therapeutics, Inc..

Action: resigned
Role: Chief Technology Officer

Exact text from the filing

On July 1, 2021, Chulho Park, Ph. D., provided notice to the Company of his intention to resign as the Chief Technology Officer of the Company, to be effective immediately.

View on SEC.gov

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-016105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.